400
Participants
Start Date
January 1, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
June 30, 2028
Low intensity treatment options
"Reference options for a combined regimen include C-R2, C-R-mini-CHOP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. .Single-drug maintenance is recommended to last 24 weeks"
Conventional immunochemotherapy regimen
"Reference options for a combined regimen include CR-CHOP, C-Pola-R-CHP, etc.~Subjects whose efficacy is assessed as CR after the end of induction therapy will enter consolidation therapy. Tucidinostat maintenance therapy or autologous hematopoietic stem cell transplantation may be an option. Tucidinostat maintenance therapy will be performed every 3 weeks. Single-drug maintenance is recommended to last 24 weeks"
RECRUITING
No. 197 Ruijin 2nd Road, Huangpu District, Shanghai, Shanghai
Ruijin Hospital
OTHER